Replimune Group
REPLClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-03-312025-06-302025-09-302025-12-31
Research & Development (R&D)
($189.45M) ($57.84M) ($57.88M) ($53.14M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($72.18M) ($32.58M) ($26.41M) ($18.73M)
Operating Income / (Loss)
($261.63M) ($90.42M) ($84.29M) ($71.87M)
NON-OPERATING & FINANCING ITEMS
2025-03-312025-06-302025-09-302025-12-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$14.80M $3.73M $1.19M $0.63M
Income Tax Provision / (Benefit)
$0.47M $0.00M $0.00M ($0.31M)
NET INCOME / (NET LOSS)
($247.30M) ($86.69M) ($83.10M) ($70.93M)
ASSETS (CURRENT & FIXED)
2025-03-312025-06-302025-09-302025-12-31
Cash and Cash Equivalents
$111.1M$97.4M$102.3M$123.0M
Short-Term Marketable Investments
$372.7M$306.0M$221.3M$146.2M
Total Liquid Cash Resources
$483.8M$403.3M$323.6M$269.1M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$8.4M$8.2M$8.3M$8.3M
Total Current Assets
$495.9M$413.4M$333.7M$280.4M
Property, Plant and Equipment, Net
$13.7M$14.7M$14.7M$13.8M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$551.3M$469.5M$389.4M$333.6M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-03-312025-06-302025-09-302025-12-31
Accounts Payable
$12.5M$15.5M$6.4M$5.6M
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$62.4M$59.6M$52.9M$50.1M
Long-Term Corporate Debt Balances
$46.4M$46.8M$47.2M$47.6M
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$26.7M$26.4M$26.0M$25.3M
Total Liabilities Block
$135.5M$132.8M$126.1M$123.1M
Total Stockholders' Equity
$415.8M$336.7M$263.3M$210.5M
TOTAL LIABILITIES & EQUITY
$551.3M$469.5M$389.4M$333.6M
HISTORICAL RATIO ANALYSIS
2025-03-312025-06-302025-09-302025-12-31
Current Liquidity Ratio
7.95x 6.94x 6.31x 5.60x
R&D Expenditure Flow
$189.4M$57.8M$115.7M$168.9M
Net Income / (Loss)
($247.30M) ($86.69M) ($83.10M) ($70.93M)
Depreciation & Amortization
$3.50M $0.87M $0.80M $0.80M
Stock-Based Compensation
$35.04M $8.76M $17.10M $24.15M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
$0.25M ($0.23M) ($0.09M) ($0.13M)
Change in Payables & Clinical Accruals
$9.94M $3.77M ($5.17M) ($5.89M)
Other Operating Source / (Use) Changes
$6.31M ($3.49M) ($87.77M) ($172.18M)
Net Cash from Operating Activities
($192.25M) ($77.02M) ($158.23M) ($224.18M)
INVESTING ACTIVITIES
2025-03-312025-06-302025-09-302025-12-31
Capital Expenditures (CapEx)
— — — —
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
($23.80M) $65.05M $149.22M $224.34M
FINANCING ACTIVITIES
2025-03-312025-06-302025-09-302025-12-31
Proceeds from Issuing Debt Instruments
$0.00M — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$155.73M $0.00M $0.00M —
Net Cash from Financing Activities
$252.40M ($0.16M) $0.17M $10.62M
NET CONSOLIDATED CHANGE IN CASH
$36.66M ($13.74M) ($8.82M) $11.83M